))
#37 - Colin Weller, VP & GM Evidence Platform at Medable
Manage episode 413023366 series 3478706
Content provided by Slice of Healthcare LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Slice of Healthcare LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Join us on the latest episode! Our Guest: Colin Weller, VP & GM of Evidence Platform at Medable.
What you'll get out of this episode:
- Introduction of Colin Weller: Vice President and GM of Evidence Platform at Medable, Colin Weller discusses his role in advancing clinical research technology to streamline drug approvals.
- Challenges in Drug Development: Weller details the stagnant pace of drug development, highlighting the industry's need for innovation to improve efficiency and reduce costs.
- Medable's Ambitious Goals: Aiming to increase the number of drugs approved annually by tenfold through advanced SAS technology and AI, setting a new industry standard.
- Innovations in Clinical Trials: Medable has already cut study startup times by 50%, utilizing AI and automation to overhaul traditional processes.
- Future of Digital Clinical Trials: Weller predicts significant advancements in decentralized and digital trials, enhancing patient accessibility and data quality.
To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/colin-weller-294ab58/
Company LinkedIn: https://www.linkedin.com/company/medable-inc-/
Website: https://www.medable.com/
Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/
40 episodes
Share
